RNS Number : 5467W
Shield Therapeutics PLC
17 April 2019

Shield Therapeutics plc
("Shield" or the "Company")

PDMR Acquisition of Shares and Additional Listing

London, UK, 17 April 2019. Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that it issued and allotted 223,690 Ordinary Shares of 1.5p each following the exercise of options under the Shield Therapeutics plc 2016 Long-Term Incentive Plan and the Shield Therapeutics Retention and Performance Share Plan.

Carl Sterritt, Chief Executive Officer of the Company, has on 16 April 2019 exercised options held under The Shield Therapeutics plc 2016 Long-Term Incentive Plan to acquire 123,690 Ordinary Shares in the Company. Following the transaction, Mr Sterritt holds 10,198,951 shares, representing 8.71% of the Company's issued share capital. The remaining 100,000 Ordinary Shares were allotted following the exercise of options by other staff members.

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 25 April 2019. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

Following admission, the Company's issued share capital will comprise 117,041,488 Ordinary Shares and each Ordinary Share carries one vote. There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 117,041,488. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	**Details of the person discharging managerial responsibilities/person closely associated**	
a)	Name	Carl Sterritt
2	**Reason for the notification**	
a)	Position/status	CEO and Director of Shield Therapeutics plc
b)	Initial notification/ Amendment	Initial Notification
3	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name	Shield Therapeutics plc
b)	LEI	213800G74QWY15FC3W71
4	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b)	Nature of the transaction	Exercise of share options held under The Shield Therapeutics plc 2016 Long-Term Incentive Plan to acquire Ordinary Shares in the Company.
c)	Price(s) and volume(s)	1.5p per Ordinary Share Volumes: 123,690
d)	Aggregated information	

	-Aggregated volume -Price	123,690 £1,855.35
e)	Date of the transaction	16 April 2019
f)	Place of the transaction	Outside a trading venue

Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial Officer

Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden +44 (0)20 7418 8900

Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780
or shield@walbrookpr.com
Paul McManus / Helen Cresswell +44 (0)7980 541 893 / +44 (0)7841 917 679

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please visit www.shieldtherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be

considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the timing of future results of Feraccru trials and the timing and success of the Group's regulatory plans and commercial strategy for Feraccru. These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results, performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with the regulatory approval process, the Group's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Group disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause our views to change.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEASLXFSPNEFF